Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel in HIV-1 Seronegative Adults
Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the safety, acceptability, and PK/PD profile of
maraviroc gel following rectal and vaginal administration. The study also includes oral
exposure to maraviroc.
Phase:
Phase 1
Details
Lead Sponsor:
International Partnership for Microbicides, Inc.
Collaborators:
National Institute of Allergy and Infectious Diseases (NIAID) National Institutes of Health (NIH)